AKM GLICLAZIDE, PHARMACOR GLICLAMIRON, PHARMACOR GLICLARON, PHARMACOR GLICLAZIDE, PHARMACOR GLICLAZIDE MR (Pharmacor Pty Ltd)
Product name
AKM GLICLAZIDE, PHARMACOR GLICLAMIRON, PHARMACOR GLICLARON, PHARMACOR GLICLAZIDE, PHARMACOR GLICLAZIDE MR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
146 working days (255)
Active ingredients
gliclazide
Registration type
New generic medicine
Indication
AKM GLICLAZIDE, PHARMACOR GLICLAMIRON, PHARMACOR GLICLARON, PHARMACOR GLICLAZIDE, PHARMACOR GLICLAZIDE MR (modified release tablet) are indicated for the treatment of type II diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.
During controlled clinical trials in patients with type II diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of HbA1c.